Shandong Sanyuan Biotechnology Co Ltd
SZSE:301206
Income Statement
Earnings Waterfall
Shandong Sanyuan Biotechnology Co Ltd
Revenue
|
462.7m
CNY
|
Cost of Revenue
|
-470.6m
CNY
|
Gross Profit
|
-7.9m
CNY
|
Operating Expenses
|
-54.7m
CNY
|
Operating Income
|
-62.6m
CNY
|
Other Expenses
|
116.8m
CNY
|
Net Income
|
54.2m
CNY
|
Income Statement
Shandong Sanyuan Biotechnology Co Ltd
Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||
Revenue |
1 570
N/A
|
1 527
-3%
|
1 675
+10%
|
1 684
+1%
|
1 346
-20%
|
933
-31%
|
675
-28%
|
519
-23%
|
453
-13%
|
463
+2%
|
|
Gross Profit | |||||||||||
Cost of Revenue |
(925)
|
(868)
|
(972)
|
(1 015)
|
(872)
|
(709)
|
(580)
|
(498)
|
(459)
|
(471)
|
|
Gross Profit |
645
N/A
|
658
+2%
|
703
+7%
|
669
-5%
|
474
-29%
|
224
-53%
|
95
-58%
|
21
-78%
|
(6)
N/A
|
(8)
-36%
|
|
Operating Income | |||||||||||
Operating Expenses |
(80)
|
(70)
|
(79)
|
(72)
|
(61)
|
(50)
|
(52)
|
(44)
|
(48)
|
(55)
|
|
Selling, General & Administrative |
(24)
|
(21)
|
(27)
|
(22)
|
(22)
|
(21)
|
(23)
|
(21)
|
(22)
|
(22)
|
|
Research & Development |
(59)
|
(52)
|
(52)
|
(58)
|
(53)
|
(42)
|
(27)
|
(36)
|
(33)
|
(39)
|
|
Depreciation & Amortization |
0
|
0
|
(9)
|
0
|
0
|
0
|
(9)
|
0
|
0
|
0
|
|
Other Operating Expenses |
3
|
3
|
8
|
9
|
15
|
13
|
7
|
12
|
7
|
6
|
|
Operating Income |
565
N/A
|
589
+4%
|
624
+6%
|
597
-4%
|
413
-31%
|
174
-58%
|
43
-75%
|
(23)
N/A
|
(54)
-131%
|
(63)
-15%
|
|
Pre-Tax Income | |||||||||||
Interest Income Expense |
(11)
|
(6)
|
(4)
|
15
|
64
|
105
|
143
|
150
|
138
|
124
|
|
Non-Reccuring Items |
0
|
0
|
(1)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
Total Other Income |
(3)
|
(2)
|
0
|
0
|
(2)
|
(2)
|
(2)
|
(2)
|
(0)
|
(0)
|
|
Pre-Tax Income |
551
N/A
|
581
+5%
|
620
+7%
|
612
-1%
|
476
-22%
|
278
-42%
|
184
-34%
|
125
-32%
|
84
-33%
|
61
-27%
|
|
Net Income | |||||||||||
Tax Provision |
(76)
|
(80)
|
(84)
|
(83)
|
(64)
|
(32)
|
(20)
|
(16)
|
(6)
|
(7)
|
|
Income from Continuing Operations |
475
|
501
|
535
|
529
|
412
|
246
|
164
|
109
|
78
|
54
|
|
Net Income (Common) |
243
N/A
|
441
+81%
|
535
+21%
|
529
-1%
|
412
-22%
|
246
-40%
|
164
-33%
|
109
-34%
|
78
-28%
|
54
-30%
|
|
EPS (Diluted) |
1.2
N/A
|
2.17
+81%
|
2.65
+22%
|
2.61
-2%
|
2.03
-22%
|
1.22
-40%
|
0.82
-33%
|
0.54
-34%
|
0.39
-28%
|
0.27
-31%
|